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that immature hearts might be provided better myocardial
protection by TWBCP compared with mature hearts.
We also examined the patients with cyanosis separately
(Table 6 and Figures 7 and 8). Our data showed that no
significant differences in lactate extraction were observed
between the groups after up to 45 minutes, and the crossover
point in group T was observed between 45 and 60 minutes
of reperfusion, indicating that the effect of TWBCP on
lactate metabolism was less evident and the recovery of
lactate extraction was slower in patients with cyanosis com-
pared with the entire study group. The underlying mecha-
nisms of delayed recovery of lactate extraction could be
impaired aerobic energy metabolism or reduced lactate
washout19 from the hypertrophied myocardium in patients
with cyanosis. No significant differences in cardiac troponin
T were observed between the groups at any time point.
These data suggest that cyanotic hearts might be less ben-
efited by TWBCP compared with acyanotic hearts. How-
ever, the effects and the mechanisms of TWBCP on cya-
notic hearts remain to be elucidated.
In conclusion, our data indicate that TWBCP has cardio-
protective effects in children and adolescents, as it does in
adults, and TWBCP affords an additional myocardial pro-
tection by improvement in aerobic energy metabolism and
reduction of myocardial injury or necrosis, suggesting that
TWBCP would allow for enhanced myocardial protection in
pediatric heart surgery and should be used routinely as in
adult heart surgery.
We express our appreciation to Sachiko Kido, MD, for assis-
tance with clinical data acquisition and Takako Kanatani, MD, for
her administrative assistance. We also wish to extend our appre-
ciation to the physicians in the division of cardiac surgery of Kobe
City General Hospital for their assistance.
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Discussion
Dr B. Allen (Oak Lawn, Ill). Cardioplegic application in con-
genital heart surgery has made tremendous gains over the past 10
years; however, recovery and outcome statistics continue to point
out the need for improvements in this increasingly younger patient
population. In general, advancements in myocardial protection
strategies have benefited from the adult cardiac experience. Nev-
ertheless, in view of the structural, functional, and metabolic
differences, extrapolation of adult cardioprotective strategies to the
pediatric population may be fundamentally imprudent and poten-
tially harmful.
A terminal warm cardioplegic reperfusate is a routine part of
most adult heart procedures. In contrast, a warm blood cardiople-
gic reperfusate is rarely used in infants, perhaps because of the
belief that the infant heart is more tolerant to ischemia. Dr Toyoda
and his colleagues are to be commended for investigating this
question with a randomized clinical trial. These studies are often
difficult because, unlike the experimental laboratory where vari-
ables can be precisely controlled and measured, the preoperative
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state of patients is not uniform, and the postoperative measure-
ments are less precise. This usually makes it difficult to demon-
strate differences unless they are profound. In spite of these prob-
lems, their data support several experimental studies and
demonstrate that a terminal warm cardioplegic reperfusate is ben-
eficial in the clinical pediatric population.
Numerous studies have documented a higher mortality and
morbidity rate in infants with cyanotic hearts, and these hearts are
often less tolerant to ischemia and more dependent on the method
of myocardial protection. Did you notice any differences between
patients with and without cyanosis?
Reperfusion injury is often related to the length of ischemia
and, therefore, crossclamp time. Was there any difference in the
outcome variables between groups as a function of crossclamp
time?
The average age of these patients was 5.5 years, and therefore
many of these hearts may not be significantly different from adults.
Can you please comment on this therapy in your younger patients?
Did you notice any difference between the younger and older
patients in the efficacy of this treatment?
We recently demonstrated a modest improvement in neonatal
piglets receiving a terminal warm cardioplegic reperfusate after
cold cardioplegic arrest. However, we noted the beneficial effect
was markedly enhanced when the amino acid aspartate and gluta-
mate were added. Indeed, this improvement was significantly
greater than when these same amino acids were added to the
terminal reperfusate in adult hearts, implying that they were more
effective in younger patients. Do you have any experience with the
use of amino acids, and could you please comment?
In summary, this is an important study because it is only one of
a small number of studies that have examined a specific myocar-
dial protection strategy in the pediatric population. I believe it is
only from studies such as this that we will be able to determine the
optimal method of protecting the pediatric heart, instead of blindly,
and often uncritically, adopting adult cardioplegic strategies.
Dr Toyoda. In this study, we had only 3 neonates, so we
couldn’t draw any conclusions for neonatal hearts. However, we
examined the patients whose ages were less than 2 years.
We had 13 patients in group C and 9 patients in group T, and
similar results were observed with the incidence of spontaneous
defibrillation and the inotropic support at the time of weaning from
cardiopulmonary bypass. Interestingly, the effect of terminal warm
blood cardioplegia on lactate metabolism was more evident in the
younger patients. As you can see, the crossover point from nega-
tive to positive was observed at 20 minutes of reperfusion, which
was 10 minutes earlier than that in the entire study group. Also,
cardiac troponin T was significantly decreased in the terminal
warm blood cardioplegia group at any time point. So, our data
suggest that immature hearts might be provided better myocardial
protection by terminal warm blood cardioplegia compared to older
hearts.
Regarding the first question, cyanosis versus acyanosis, we had
26 patients with cyanosis in both groups, and again similar results
were observed in terms of spontaneous defibrillation and inotropic
support. Interestingly, in patients with cyanosis, there were no
significant differences in lactate extraction up to 45 minutes be-
tween the groups, and the crossover point was observed between
45 and 60 minutes, which moved significantly to the right. Also, no
significant difference in cardiac troponin T was observed between
the groups.
We had 26 patients without cyanosis in group C and 25 in
group T. The effect of terminal warm blood cardioplegia on lactate
metabolism was more evident in patients in the acyanotic group.
The crossover point was observed between 10 and 20 minutes,
which was significantly earlier than that observed in patients with
cyanosis. Also, cardiac troponin T was significantly decreased at 0
and 1 hour after reperfusion in patients in the acyanotic group. So,
these data suggest that patients with cyanosis might be less ben-
efited by terminal warm blood cardioplegia compared with patients
in the acyanotic group. Regarding the aortic crossclamp time, we
could not find any correlation between the aortic crossclamp time
and the effect of terminal warm blood cardioplegia.
Finally, we didn’t add amino acids to our terminal warm blood
cardioplegia. I know Dr Allen and colleagues have reported the
effectiveness of amino acids. In this particular study, however, we
simply investigated the effect of warm blood cardioplegia with the
same composition as cold blood cardioplegia.
Dr Emile A. Bacha (Chicago, Ill). Would you comment on the
temperature difference between your warm cardioplegia and the
temperature of the myocardium itself? You mentioned that the
myocardium had a temperature of 9°C, so you’re hitting myocar-
dial cells that are 9°C with a 35°C perfusate. When we cool and
warm patients, as you know, we’re very careful to keep the
temperature difference between perfusate and body temperature at
most 10°C difference for fear of harming the cells, and I’m
wondering whether you could comment on that particular aspect of
your strategy.
Dr Toyoda. We measured myocardial temperature while in-
fusing terminal warm blood cardioplegia. Myocardial temperature
was increased from 9.6°C to about 20°C. But, as you can see, the
functional recovery and the recovery of rhythm in patients treated
with terminal warm blood cardioplegia were better than in patients
without terminal warm blood cardioplegia. We didn’t find any
detrimental effect by this warm temperature.
Dr Richard A. Jonas (Boston, Mass). Dr Toyoda, have you
considered using thermodilution cardiac output in the first 24 hours
after operation to assess myocardial protection? I’ve been sur-
prised at how little this has been used as a clinical tool in studies
of this nature. We have found in our studies, which primarily have
been looking at cerebral protection, that when we place thermodi-
lution catheters, we obtain very reproducible results. The ther-
modilution catheter has been a very sensitive clinical instrument
for us that has demonstrated, for example, improved myocardial
protection with a higher perfusate hematocrit on bypass. Have you
considered using a thermodilution catheter to measure the cardiac
output?
Dr Toyoda. Instead of the thermodilution catheter, we used a
left atrial line and pulmonary arterial line to measure the left atrial
and pulmonary arterial pressures. Because we believe cardiac
output is definitely a good marker to treat patients after operation,
we will consider using the thermodilution catheter.
Dr Jonas. Okay. Well, I would put in a plea for those of you
doing myocardial protection studies, it’s simply a matter of placing
a pulmonary artery line through the infundibulum of the right
ventricle and a right atrial line. And by injection of ice saline
solution, it’s possible to get regular thermodilution outputs. It’s
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certainly not a regular Swan-Ganz catheter (Baxter Healthcare
Corp., Edwards Div., Irvine, Calif.) like you would use in an adult,
but we found it to be an extremely low-risk test.
Dr William M. DeCampli (Philadelphia, Pa). You have to be
applauded for the number of patients in your study: 100 is a great
number. That also implies, however, that you probably could have
used formal multivariate analysis to examine these data rather than
a series of univariate studies. Your clamp times must have had a
fair amount of spread, because you did some quite simple opera-
tions, atrial septal defect closures, all the way up to repairs of
pulmonary atresia. So that I would think that a more formal look
at whether there were significant interactions between the duration
of ischemia, the total time for cardiopulmonary bypass, and the
method of cardioplegia might be worth trying if you have haven’t
already done so.
Also, with regard to certain outcome variables, such as the
incidence of using inotropes, I think that blindedness in a study
like this can be very important, because no one has a very rigorous
set of criteria for instituting inotropic support on weaning bypass.
In a study like this, it is possible to blind that final 3 minutes with
regard to whether you were actually infusing or not infusing, and
it might be worth trying.
Finally, with regard to the lactate production, in a study that we
had done previously we looked at the effect of blood cardioplegia
on early coronary vasodilation during that terminal phase. I’m
wondering if the lag in the transition point of lactate production
may have been just the effect of delayed opening up of some of the
distal coronary beds so that you have delayed washout of lactate,
to the extent that the effect does not represent increased myocar-
dial damage or increased lactate production so much as it repre-
sents delayed washout of lactate.
Dr Toyoda. We have not done multivariate analysis yet, so we
will do that. Regarding criteria for instituting inotropic support at
the time of weaning patients from cardiopulmonary bypass, we
make every effort to avoid using inotropic support because we
believe inotropes are harmful for myocardial cells recovering from
ischemic injury. The most important thing we did was take enough
time for empty beating after completion of intracardiac repair. The
average time for empty beating was 34 minutes. Also, of course,
we rigorously optimized rhythm, preload, and afterload before we
tried to wean patients from cardiopulmonary bypass. We wean
patients from cardiopulmonary bypass if systolic blood pressure is
greater than 50 to 70 mm Hg, depending on a patient’s age, with
left atrial pressure between 10 and 12 mm Hg. We also believe that
blindedness with regard to whether the patients were receiving
terminal warm blood cardioplegia can be very important.
With regard to the lactate production, delayed washout could be
the mechanism of this result. We didn’t measure the coronary flow
in this study so we couldn’t comment on that. However, we believe
the effect on the lactate extraction does represent, at least in part,
increased myocardial damage based on clinical outcomes, as well
as the results of cardiac troponin T and fatty acid binding protein.
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